Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are over 18 years old
- You have been diagnosed through a tissue test with a specific type of advanced ovarian cancer called high-grade serous ovarian cancer (at stage FIGO IIIB or IIIC), where surgery is a possible treatment option, with or without prior chemotherapy given before surgery
- You are willing and able to attend planned visits, follow the treatment plan, and complete required tests and study procedures
- You have read, understood, and signed a consent form agreeing to take part
- You are covered by a French health insurance scheme
Who may not be able to join:
- Your cancer is at an earlier stage than FIGO IIIB, or the cancer has spread to areas outside the abdomen
- You will not be having surgery as part of your treatment
- Regular follow-up appointments would not be possible for you due to psychological, family, social, or geographical reasons
- You are currently under a legal protection measure such as guardianship or curatorship (confirm with trial site)
- You are pregnant or currently breastfeeding
- You have had another type of cancer diagnosed within the past 5 to 10 years (confirm with trial site for exact timeframe that applies to your situation)
⚠️ Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: NOUGARET Stephanie, MD, INSTITUT REGIONAL DU CANCER DE MONTPELLIER Cancer de Montpellier
Phone: 0467613102
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
the integration of in vivo and ex vivo of MRI with histology and molecular assessments to advance non-invasive characterization of tumor heterogeneity in high-grade serous ovarian cancer.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.